OptimizeRx (OptimizeRx) EBIT : $-23.71 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx EBIT?

OptimizeRx's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-8.21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-23.71 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. OptimizeRx's annualized ROC % for the quarter that ended in Dec. 2023 was -2.76%. OptimizeRx's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -160.30%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. OptimizeRx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -10.80%.

OptimizeRx EBIT Historical Data

The historical data trend for OptimizeRx's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx EBIT Chart

OptimizeRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-2.89

-2.14

0.36

-11.44

-23.71

OptimizeRx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-0.01	-7.06	-4.88	-3.55	-8.21

Competitive Comparison of OptimizeRx's EBIT

For the Health Information Services subindustry, OptimizeRx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OptimizeRx's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OptimizeRx's EV-to-EBIT falls into.

OptimizeRx EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.71 Mil.

OptimizeRx (NAS:OPRX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

OptimizeRx's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-8.092 * ( 1 - 64.72% )	/	( (52.902	+	154.034)	/ 2 )
=	-2.8548576	/	103.468
=	-2.76 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	123.929	-	7.485	-	( 63.542	-	max(0, 7.702	-	87.39	+	63.542	))
=	52.902

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	183.374	-	15.488	-	( 13.852	-	max(0, 17.881	-	54.331	+	13.852	))
=	154.034

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

OptimizeRx's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-32.844	/	( ( (0.298 + max(16.174, 0))	+	(0.722 + max(23.784, 0)) )	/	2 )
=	-32.844	/	( ( 16.472	+	24.506 )	/	2 )
=	-32.844	/	20.489
=	-160.30 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(20.839	+	0	+	3.009)	-	(7.485	+	0.188	+	0.0010000000000003)
=	16.174

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(36.253	+	0	+	3.19)	-	(15.488	+	0.172	+	-0.0010000000000012)
=	23.784

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

OptimizeRx's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-23.709	/	219.539
	=	-10.80 %

OptimizeRx EBIT Related Terms

Thank you for viewing the detailed overview of OptimizeRx's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

OptimizeRx (OptimizeRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Water Street, Suite 200, Rochester, MI, USA, 48307

Website

https://www.optimizerx.com

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Executives

Marion Odence-ford	officer: General Counsel and CCO	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco	officer: Chief Commercial Officer	260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch	officer: Chief Product Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo	officer: Chief Executive Officer	600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro	officer: Chief Commercial Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos	director	C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh	officer: COO and CFO	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore	officer: President	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler	director, officer: SVP of Product & Strategy	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker	officer: Chief Financial Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman	officer: Chief Technology Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson	director	200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas	director	38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022